Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRT106 in Recurrent/Progressive Glioblastoma
NCT07093814Phase 2Recruiting
- Sponsor
- Guangzhou Virotech Pharmaceutical
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of VRT-106 in glioblastoma (GBM), sponsored by Guangzhou Virotech Pharmaceutical. Started Sep 2025; status: recruiting.
02
Drugs
VRT-106
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07093814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07093814.